Thomas Wilke1, Antje Groth2, Andreas Fuchs3, Matthias Pfannkuche4, Ulf Maywald3. 1. Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Hochschule Wismar, Germany. Thomas.wilke@ipam-wismar.de. 2. Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM), Hochschule Wismar, Germany. 3. AOK PLUS, Dresden, Germany. 4. Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.
Abstract
PURPOSE: The aim of this study was to describe persistence with vitamin K antagonist (VKA) treatment in German atrial fibrillation (AF) patients and to identify factors which may be associated with early discontinuation of VKA therapy. METHODS: We did a retrospective cohort study based on an anonymized German claims dataset with VKA treatment-naïve AF patients, who received at least one VKA prescription. VKA therapy discontinuation was defined as a gap >180 days. RESULTS: We identified 38,076 VKA patients who started a VKA therapy (mean age 76.13 years; 56.08% female; mean CHA2DS2-VASc-Score 4.49; mean Charlson Comorbidity Index (CCI) 3.91). After four quarters since start of VKA treatment, 14,889 (39.10%) of observed patients had discontinued their VKA treatment (after eight quarters: 54.61%). Mean time until treatment discontinuation was 390.55 days. Risk of VKA discontinuation increased with the diagnosis of dementia within the first two quarters of VKA treatment [HR 1.35 (95% CI 1.29-1.40)], diagnosed alcohol or drug abuse in the baseline period [HR 1.25; 95% CI 1.18-1.33)], female gender [HR 1.08; 95% CI 1.05-1.10)], higher age (HR 1.03; 95% CI 1.03-1.03), higher CCI (HR 1.05; 95% CI 1.04-1.05), any prescription of NSAID (HR 1.07; 95% CI 1.04-1.10), and number of surgeries in the first two quarters of VKA treatment (HR 1.05; 95% CI 1.04-1.05). At least one yearly visit to a cardiologist since start of VKA treatment decreased the risk of non-persistence [HR 0.90; 95% CI 0.88-0.93] and a cancer diagnosis in the baseline period (HR 0.92; 95% CI 0.89-0.96). CONCLUSION: Non-persistence related to VKA therapy is common in AF patients. Older more comorbid female patients as well as patients who face surgeries and who do not visit a cardiologist regularly face a higher therapy discontinuation risk.
PURPOSE: The aim of this study was to describe persistence with vitamin K antagonist (VKA) treatment in German atrial fibrillation (AF) patients and to identify factors which may be associated with early discontinuation of VKA therapy. METHODS: We did a retrospective cohort study based on an anonymized German claims dataset with VKA treatment-naïve AFpatients, who received at least one VKA prescription. VKA therapy discontinuation was defined as a gap >180 days. RESULTS: We identified 38,076 VKA patients who started a VKA therapy (mean age 76.13 years; 56.08% female; mean CHA2DS2-VASc-Score 4.49; mean Charlson Comorbidity Index (CCI) 3.91). After four quarters since start of VKA treatment, 14,889 (39.10%) of observed patients had discontinued their VKA treatment (after eight quarters: 54.61%). Mean time until treatment discontinuation was 390.55 days. Risk of VKA discontinuation increased with the diagnosis of dementia within the first two quarters of VKA treatment [HR 1.35 (95% CI 1.29-1.40)], diagnosed alcohol or drug abuse in the baseline period [HR 1.25; 95% CI 1.18-1.33)], female gender [HR 1.08; 95% CI 1.05-1.10)], higher age (HR 1.03; 95% CI 1.03-1.03), higher CCI (HR 1.05; 95% CI 1.04-1.05), any prescription of NSAID (HR 1.07; 95% CI 1.04-1.10), and number of surgeries in the first two quarters of VKA treatment (HR 1.05; 95% CI 1.04-1.05). At least one yearly visit to a cardiologist since start of VKA treatment decreased the risk of non-persistence [HR 0.90; 95% CI 0.88-0.93] and a cancer diagnosis in the baseline period (HR 0.92; 95% CI 0.89-0.96). CONCLUSION: Non-persistence related to VKA therapy is common in AFpatients. Older more comorbid female patients as well as patients who face surgeries and who do not visit a cardiologist regularly face a higher therapy discontinuation risk.
Entities:
Keywords:
Anticoagulation; Atrial fibrillation; Non-persistence; Vitamin K antagonist
Authors: Valentin Fuster; Lars E Rydén; Davis S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Huezey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Sidney C Smith; Silvia G Priori; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Christopher E Buller; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Lynn G Tarkington; Clyde W Yancy Journal: Circulation Date: 2011-03-07 Impact factor: 29.690
Authors: Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns Journal: Eur Heart J Date: 2006-05-26 Impact factor: 29.983
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Martin Zalesak; Kimberly Siu; Kevin Francis; Chen Yu; Hasmik Alvrtsyan; Yajing Rao; David Walker; Stephen Sander; Gavin Miyasato; David Matchar; Herman Sanchez Journal: Circ Cardiovasc Qual Outcomes Date: 2013-08-06
Authors: Sonja V Sorensen; Sarah Dewilde; Daniel E Singer; Samuel Z Goldhaber; Brigitta U Monz; Jonathan M Plumb Journal: Am Heart J Date: 2009-06 Impact factor: 4.749
Authors: Mohammed A Mohammed; Tom Marshall; Krishnarajah Nirantharakumar; Andrew Stevens; David Fitzmaurice Journal: PLoS One Date: 2013-05-02 Impact factor: 3.240